Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
157.8 USD | +0.86% | -0.63% | -22.44% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 960.09 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-22.44% | 4.69B | C | ||
+16.65% | 133B | A- | ||
-3.76% | 11.52B | A- | ||
-4.86% | 8.3B | C | ||
+7.79% | 3.42B | C- | ||
-17.26% | 2.54B | B- | ||
-13.36% | 2.03B | - | - | |
-16.39% | 1.86B | - | ||
-31.24% | 1.59B | C- | ||
-8.10% | 1.17B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- INSP Stock
- Ratings Inspire Medical Systems, Inc.